SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$122M
Q1 2024
Positions
60
Filings on Record
39
2019–present window
Filed
May 14, 2024
original filing

Summary

Birchview Capital, LP reported $122M in U.S.-listed holdings across 60 positions for Q1 2024.

The portfolio is heavily concentrated: BMY alone accounts for 31.2% of reported value.

Compared with Q4 2023, the fund opened 2 new positions and exited 1.

Portfolio Metrics

Turnover
+10.2%
vs prior filed quarter
Top-10 Concentration
+68.0%
share of reported value
Largest Position
+31.2%
Bristol Myers Squibb
New / Exited
2 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.7%Other: 12.3%
  • Common Stock · 87.7% · $107M
  • Other · 12.3% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AXSMAXSOME THERAPEUTICS INCNEW+4.0K4.0K+$319,200$319,200
CERO THERAPEUTICS HOLDINGS INCNEW+13.0K13.0K+$39,824$39,824
DCGODOCGO INCADDED+310.0K460.0K+$1M$2M
CHRSCOHERUS BIOSCIENCES INCADDED+160.0K270.0K+$279,000$645,300
IMGNEURIMMUNOGEN INCSOLD OUT−188.0K0−$6M$0
CYTKCYTOKINETICS INCTRIMMED−15.0K10.0K−$1M$701,100
LQDALIQUIDIA CORPORATIONTRIMMED−10.0K10.0K−$93,100$147,500
ACCELERATE DIAGNOSTICS INCADDED+100.0K325.2K−$560,950$321,986

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM31.15%$38M703.6K
2NBIXNEUROCRINE BIOSCIENCES INChistory →COM8.70%$11M77.2K
3BIODESIX INCCOM5.88%$7M5.04M
4ELUTELUTIA INChistory →COM4.26%$5M1.66M
5ACADACADIA PHARMACEUTICALS INChistory →COM3.78%$5M250.4K
6OVVOVINTIV INChistory →COM3.57%$4M84.2K
7PROTHENA CORP PLCSHS3.43%$4M169.6K
8QDEL*QUIDELORTHO CORPhistory →COM2.55%$3M65.2K
9SILKUSDSILK ROAD MEDICAL INChistory →COM2.36%$3M158.1K
10STOKSTOKE THERAPEUTICS INChistory →COM2.31%$3M210.0K
11PHRPHREESIA INChistory →COM2.24%$3M114.7K
12UTHUNITED THERAPEUTICS CORPhistory →COM2.06%$3M11.0K
13MASI*MASIMO CORPhistory →COM1.83%$2M15.3K
14FHTXFOGHORN THERAPEUTICS INChistory →COM1.76%$2M320.9K
15HROWHARROW HEALTH INChistory →COM1.62%$2M150.0K
16DCGODOCGO INChistory →COM1.52%$2M460.0K
17INBXUSDINHIBRX INChistory →COM1.38%$2M48.4K
18ETRNUSDEQUITRANS MIDSTREAM CORPORATIOhistory →COM1.36%$2M133.1K
19AXGNAXOGEN INChistory →COM1.14%$1M173.0K
20PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.13%$1M48.0K
21ALKERMES PLCSHS1.11%$1M50.0K
22HTDCORCEPT THERAPEUTICS INChistory →COM1.03%$1M50.0K
23ATECALPHATEC HOLDINGS INCCOM0.99%$1M88.0K
24TXG10X GENOMICS INCCL A COM0.92%$1M30.0K
25APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.86%$1M18.0K
26PXDEURPIONEER NATURAL RESOURCES COCOM0.81%$997,5003.8K
27TVTXTRAVERE THERAPEUTICS INCCOM0.77%$940,620122.0K
28PGNYPROGYNY INCCOM0.69%$839,30022.0K
29KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.58%$709,446469.8K
30CYTKCYTOKINETICS INCCOM0.57%$701,10010.0K
31CHRSCOHERUS BIOSCIENCES INCCOM0.53%$645,300270.0K
32ARVNARVINAS INCCOM0.51%$619,20015.0K
33KINIKSA PHARMACEUTICALS LTDCOM0.48%$591,90030.0K
344XC1KALVISTA PHARMACEUTICALS INCCOM0.45%$545,56046.0K
35SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.40%$492,20010.0K
36KROSKEROS THERAPEUTICS INCCOM0.38%$463,4007.0K
37XENEXENON PHARMACEUTICALS INCCOM0.35%$430,50010.0K
38CGEMCULLINAN ONCOLOGY INCCOM0.35%$427,94325.1K
39BLUEBIRD BIO INCCOM0.34%$411,136321.2K
40HALOHALOZYME THERAPEUTICS INCCOM0.33%$406,80010.0K
41BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.33%$402,7927.4K
42GTHXEURG1 THERAPEUTICS INCCOM0.28%$345,60080.0K
43AM6AMICUS THERAPEUTICS INCCOM0.27%$329,84028.0K
44SRPTSAREPTA THERAPEUTICS INCCOM0.26%$323,6502.5K
45ACCELERATE DIAGNOSTICS INCCOM0.26%$321,986325.2K
46AXSMAXSOME THERAPEUTICS INCCOM0.26%$319,2004.0K
47CSTLCASTLE BIOSCIENCES INCCOM0.25%$310,10014.0K
48XNCRXENCOR INCCOM0.22%$272,19912.3K
49ZNTLZENTALIS PHARMACEUTICALS INCCOM0.21%$252,16016.0K
50WAVE LIFE SCIENCES LTDSHS0.20%$246,80040.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.